Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Hanneke J van der Woude"'
Autor:
Rienk Y. J. Tamminga, Jan G. Zijlstra, Tjip S. van der Werf, John H. J. M. Meertens, Stefano Rosati, E.A. Verschuuren, Hanneke J van der Woude
Publikováno v:
Chest, 130(1), 291-295. ELSEVIER SCIENCE BV
Autor:
Hanneke J van der Woude, Marinus van Hulst, R. Aalbers, Johan Zaagsma, Trea H Winter, Dirkje S. Postma
Publikováno v:
Chest. 127:818-824
Introduction β-Blockers are known to worsen FEV 1 and airway hyperresponsiveness (AHR) in patients with asthma. Both characteristics determine the outcome of COPD, a disease with frequent cardiac comorbidity requiring β-blocker treatment Objective
Publikováno v:
Respiratory Medicine, 98(9), 816-820. W B SAUNDERS CO LTD
Virtually all asthma patients use bronchodilators. Formoterol and salbutamol have a rapid onset of bronchodilating effect, whereas salmeterol acts slower. We studied the onset of improvement of dyspnoea sensation after inhalation with these bronchodi
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 17:89-95
Inhalers containing corticosteroids and long-acting beta2-agonists are becoming increasingly important in asthma management. A rapid effect is important to patients, particularly during exacerbations. We compared the onset of bronchodilation and pati
Autor:
Hanneke J van der Woude, R. Aalbers
Publikováno v:
American Journal of Respiratory Medicine. 1:55-74
Salmeterol and formoterol are both long-acting beta(2)-adrenoceptor agonists (beta(2)-agonists). They both provide excellent bronchodilating and bronchoprotective effects in patients with asthma but their are some differences between these two long-a
Publikováno v:
Respiratory Research, Vol 11, Iss 1, p 66 (2010)
Respiratory Research, 11. BioMed Central
Respiratory research, 11. BioMed Central
Respiratory Research
Respiratory Research, 11. BioMed Central
Respiratory research, 11. BioMed Central
Respiratory Research
Background The budesonide/formoterol combination is successfully used for fast relief of asthma symptoms in addition to its use as maintenance therapy. The temporarily increased corticosteroid dose during increasing inhaler use for symptom relief is
Autor:
Hanneke J, van der Woude, Johan, Zaagsma, Dirkje S, Postma, Trea H, Winter, Marinus, van Hulst, René, Aalbers
Publikováno v:
Chest. 127(3)
beta-Blockers are known to worsen FEV(1) and airway hyperresponsiveness (AHR) in patients with asthma. Both characteristics determine the outcome of COPD, a disease with frequent cardiac comorbidity requiring beta-blocker treatment.To determine the e
Autor:
Hanneke J. Van der Woude, Tjark Ebels, Isabelle C. Van Gelder, Robert G. Tieleman, Johan Brügemann, Jan G. Grandjean, Harry J.G.M. Crijns, Pieter J de Kam
Publikováno v:
American Journal of Cardiology, 78(10), 1140-1144. EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
Chronic atrial fibrillation (AF) occurs often in the setting of mitral and aortic valve disease. Eventually, these patients undergo valve replacement which improves cardiac function but does not prevent AF. This study investigates which patient may b
Autor:
R. Aalbers, Hanneke J van der Woude
Publikováno v:
Chest. 119:309
Autor:
R. Aalbers, Hanneke J van der Woude
Publikováno v:
Respiratory Medicine. (4):871-872